Most of the Asian equity benchmarks are trading lower in early deals on Friday, escalation in tensions in the Middle East and the report that Gilead Sciences' experimental coronavirus drug remdesivir flopped in its first randomized clinical trial, weighed the investor sentiments. Japan's Nikkei is subdued in line with the weaker cues from US stock markets. Among the other Asian markets, Hong Kong, Singapore, South Korea, Indonesia, Shanghai, and Malaysia are trading in red. On the other hand, Taiwan is in positive territory.
Nikkei 225 slipped 226.37 points, 1.17% to 19,203.07, Straits Times fell 22.12 points or 0.87% to 2,520.25, Hang Seng declined 126.07 points or 0.53% to 23,851.25, KOSPI Index weakened 23.72 points or 1.24% to 1,891.01, Jakarta Composite dropped 37.34 points or 0.81% to 4,556.21, Shanghai decreased 22.30 points or 0.79% to 2,816.20, and FTSE Bursa Malaysia KLCI down by 7.64 points or 0.55% to 1,374.00.
On the flip side, Taiwan Weighted rose by 2.87 points or 0.03% to 10,369.38.
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: